

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Kevin P. BAKER, et al.

Application Serial No. 10/015,387

Filed: December 12, 2001

For: **SECRETED AND
TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**



Examiner: Fredman, Jeffrey Norman

Art Unit: 1637

Confirmation No: 9861

Attorney's Docket No. 39780-2830 P1C54

Customer No. 35489

EXPRESS MAIL LABEL NO. EL 977 609 574 US

DATE MAILED: NOVEMBER 8, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

11/12/2004 HAL111 00000021 081641 10015387
01 FC:1806 180.00 DA

☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; **or**

☒ a fee of **\$180.00** as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**

C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39780-2830 P1C54).**

Respectfully submitted,

Dated: November 8, 2004

By: _____

Anna L. Barry, Ph.D. (Reg. No. 51,436)


HELLER EHRMAN WHITE & MCAULIFFE LLP

275 Middlefield Road

Menlo Park, California 94025-3506

Telephone: (650) 324-7000

Facsimile: (650) 324-0638



INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.: 39780-2830 P1C54			SERIAL NO.: 10/015,387		
			APPLICANT : Kevin P. BAKER, et al.					
			FILING DATE: December 12, 2001			GROUP: 1637		
U.S. PATENT DOCUMENTS								
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
FOREIGN PATENT DOCUMENTS								
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
						<input type="checkbox"/>	<input type="checkbox"/>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	Ahlgren, Ulf, et al., " β -Cell-specific inactivation of the mouse <i>Ipfl/Pdx1</i> gene results in loss of the β -Cell phenotype and maturity onset diabetes", Genes & Development, Vol. 12, pp. 1763-1768, 1998.							
	Boj, Sylvia F., et al., "A transcription factor regulatory circuit in differentiated pancreatic cells", PNAS, Vol. 98, No. 25, December 4, 2001.							
	Eto, Yoko, et al., "Anti-Mitogenic Effects of Sarpogrelate In Cultured Rat Mesangial Cells", Life Sciences, Vol. 60, No. 11, pp PL 193-199, 1997.							
	Kashgarian, Michael, et al., "Mesangium and Glomerular Disease", Laboratory Investigation, Vol. 52, No. 6, pp 569-571, 1985.							
	Gohda, Tomohito, et. al., "Dilazep Hydrochloride, an Antiplatelet Drug, Inhibits Lipopolysaccharide-Induced Mouse Mesangial Cell IL-6 Secretion and Proliferation", Kidney & Blood Pressure Research, Vol. 24, pp 33-38, 2001.							
	Leibowitz, Gil, et al. "IPF1/PDX1 Deficiency and β -Cell Dysfunction in <i>Psammomys obesus</i> , and Animal With Type 2 Diabetes, Vol. 50, August 2001.							
	Mene, Paolo, et al., "Physiology of the Mesangial Cell", Physiological Reviews, Vol. 69, No. 4, October 1989.							
	Offield, Martin, F., "PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum", Department of Cell Biology", Vol. 122, pp 983-995, 1996.							
	Ono, Takahiko, et al., "Broad Antiproliferative Effects of Benidipine on Cultured Human Mesangial Cells in Cell Cycle Phases", American Journal of Nephrology", Vol. 22, pp 581-586, 2002.							
	Ruef, Christian, et al., "Interleukin 6 is an autocrine growth factor for mesangial cells", Kidney International, Vol. 38, pp 249-257, 1990.							
	Striker, Liliane J., et al., "The Contribution of Glomerular Mesangial Cells to Progressive Glomerulosclerosis", Seminars in Nephrology, Vol. 9, No. 4, pp 318-328, December 1989.							
EXAMINER			DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.: 39780-2830 P1C54		SERIAL NO.: 10/015,387	
			APPLICANT : Kevin P. BAKER, et al.			
			FILING DATE: December 12, 2001		GROUP: 1637	
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	<div style="text-align: center; font-size: small;">TRANSLATION</div> <div style="display: flex; justify-content: space-around;"> YES NO </div>
						<input type="checkbox"/> <input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Wolf, Gunter, et al., "Angiotensin II Stimulates the Proliferation and Biosynthesis of Type 1 Collagen in Cultured Murine Mesangial Cells", American Journal of Pathology, Vol 140, No. 1, January 1992.					
	Zalzman, Michal, et al., "Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells", PNAS, Vol. 100, No. 12, June 10, 2003.					
EXAMINER			DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.